Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2016-12-03 Regulatory Filings
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
S-3/A
Regulatory Filings Classification · 100% confidence The document is a Form S-3/A Registration Statement Amendment No. 2 filed with the SEC by Arrowhead Pharmaceuticals, Inc. It is a regulatory filing related to securities registration under the Securities Act of 1933. The text includes details about the registration statement, exhibits, indemnification of directors and officers, and undertakings related to the registration process. It is not a financial report, earnings release, or any other report type but a regulatory filing for securities registration purposes. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but the actual filing document.
2016-12-03 English
S-3/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 2 to a Form S-3 Registration Statement filed with the SEC by Arrowhead Pharmaceuticals, Inc. It includes details about the registration of securities under the Securities Act of 1933, exhibits such as consents from auditors and legal counsel, and undertakings related to the registration process. The document is a regulatory filing related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report but a registration statement amendment. Therefore, it fits best under Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but a formal SEC filing for securities registration.
2016-12-03 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the departure of a Chief Scientific Officer and a press release about discontinuing development of certain drug candidates. There are no financial statements or detailed financial data present. The document is short (2500 characters) and serves as an announcement of corporate events rather than a full report. The key event is a management change (departure of an officer). Therefore, the most appropriate classification is Board/Management Information (MANG).
2016-12-01 English
S-3/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC by Arrowhead Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The text includes details about the securities to be offered (common stock, preferred stock, debt securities, warrants), the registration process, and disclaimers about the offering. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement amendment, not just an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear identification of the form and purpose.
2016-11-24 English
S-3/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A Registration Statement Amendment No. 1 filed with the SEC by Arrowhead Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The text includes details about the securities being registered, selling stockholders, and related agreements. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and offering. Therefore, it fits best under the category Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2016-11-24 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a correspondence letter dated November 23, 2016, addressed to the SEC regarding comments on a Registration Statement on Form S-3 filed by Arrowhead Pharmaceuticals. It discusses procedural compliance related to filing exhibits and amendments to the registration statement. The content is a regulatory response letter and does not contain financial data, earnings, management discussion, or report content. It is short (2504 characters) and serves as a regulatory filing correspondence rather than a financial report or announcement. Therefore, it fits best under Regulatory Filings (RNS).
2016-11-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.